Castle Biosciences (CSTL) 2026 Global Healthcare Conference summary

Business overview and recent performance

• Focuses on molecular diagnostics with tests impacting physician decisions and patient outcomes in dermatology and gastroenterology.

• Main revenue drivers are melanoma and TissueCypher tests, both showing strong progress and sector-leading adjusted gross margins.

• No changes in long-term outlook for 2026; macro environment and inflation remain stable.

TissueCypher growth and market dynamics

• TissueCypher test volumes grew 63% year-over-year, with expectations for 50%-52% annual growth.

• Penetration is early; adoption increases as practices standardize use, with workflow integration being key.

• Addressable market is 415,000 patients annually, with current penetration at 10%-12%, aiming for mid-teens by year-end.

• No lab capacity constraints; Pittsburgh lab is scaled ahead of demand.

• Long-term penetration modeled at 60%-65% of the addressable market.

Commercial and operational strategy

• Expanded gastroenterology sales territories; full productivity expected by 2027 after recent hiring.

• New reps reach full productivity in about six months.

• Most payers lack formal policies for TissueCypher; broader adoption is needed for coverage.